Wang Shiyu, Wang Yanan, Liu Xiangnan, Yang Yongbin, Wu Sufang, Liu Yuan
Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China.
Cancers (Basel). 2022 Apr 8;14(8):1872. doi: 10.3390/cancers14081872.
Sulforaphane (SFN) is one kind of phytochemical anticancer drug. It inhibits cancer cell proliferation and promotes cell apoptosis while the mechanism behind is still uncertain. We aimed to explore its downstream target and the radiotherapy sensitization mechanism in cervical cancer.
We treated established cervical cancer cells line (SiHa, HeLa, C33A) with SFN followed by irradiation, and explored its survival, apoptosis, and DNA damage repair in vitro and validated the radiosensitivity of SFN treatment in vivo. We conducted mRNA sequencing to identify differentially expressed mRNAs after SFN treatment. We further investigated SFN downstream target and its involvement in DNA damage repair under irradiation.
We found that SFN inhibited the survival of cervical cancer cells under radiotherapy treatment in vitro and prolonged the survival period after radiotherapy in the mouse tumorigenic model. SFN increased the protein expression of LATS2 and promoted apoptosis of cervical cancer cells. Overexpressed LATS2 decreased the cellular survival rate of cervical cancer cells. Additionally, SFN treatment and LATS2 overexpression prevented MDC1 and Rad51 from accumulating in the nucleus in cervical cancer cells after being exposed to ionized radiation. LATS2 loss intervened with SFN-alleviated RAD51 and MDC1 nucleus accumulation and resumed the repairment of DNA damage.
We identified SFN as cervical cancer cells radiotherapy sensitizer and LATS2 served as a downstream target of SFN treatment. SFN treatment resulted in the inhibition of the homologous recombination (HR) pathway, and LATS2 has an indispensable contribution to this SFN-facilitated radiotherapy sensitization.
萝卜硫素(SFN)是一种植物化学抗癌药物。它可抑制癌细胞增殖并促进细胞凋亡,但其背后的机制仍不明确。我们旨在探索其在宫颈癌中的下游靶点及放射增敏机制。
我们用SFN处理已建立的宫颈癌细胞系(SiHa、HeLa、C33A),随后进行照射,在体外探索其生存、凋亡及DNA损伤修复情况,并在体内验证SFN治疗的放射敏感性。我们进行mRNA测序以鉴定SFN处理后差异表达的mRNA。我们进一步研究SFN的下游靶点及其在照射下参与DNA损伤修复的情况。
我们发现SFN在体外放疗处理下抑制宫颈癌细胞的生存,并在小鼠致瘤模型中延长放疗后的生存期。SFN增加了LATS2的蛋白表达并促进宫颈癌细胞凋亡。过表达LATS2降低了宫颈癌细胞的细胞存活率。此外,SFN处理和LATS2过表达可防止宫颈癌细胞在受到电离辐射后MDC1和Rad51在细胞核中积累。LATS2缺失干预了SFN减轻的RAD51和MDC1细胞核积累,并恢复了DNA损伤的修复。
我们确定SFN为宫颈癌细胞放疗增敏剂,LATS2是SFN治疗的下游靶点。SFN治疗导致同源重组(HR)途径受到抑制,并且LATS2对这种SFN促进的放疗增敏作用有不可或缺的贡献。